AU781505B2 - Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof - Google Patents

Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof Download PDF

Info

Publication number
AU781505B2
AU781505B2 AU72799/00A AU7279900A AU781505B2 AU 781505 B2 AU781505 B2 AU 781505B2 AU 72799/00 A AU72799/00 A AU 72799/00A AU 7279900 A AU7279900 A AU 7279900A AU 781505 B2 AU781505 B2 AU 781505B2
Authority
AU
Australia
Prior art keywords
migraine
active ingredient
lipoic acid
administered
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU72799/00A
Other languages
English (en)
Other versions
AU7279900A (en
Inventor
Harald Borbe
Jurgen Engel
Michael Lobisch
Manfred Peukert
Jean Schoenen
Klaus Wessel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meda Pharma GmbH and Co KG
Original Assignee
Viatris GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris GmbH and Co KG filed Critical Viatris GmbH and Co KG
Publication of AU7279900A publication Critical patent/AU7279900A/en
Application granted granted Critical
Publication of AU781505B2 publication Critical patent/AU781505B2/en
Assigned to MEDA PHARMA GMBH & CO. KG reassignment MEDA PHARMA GMBH & CO. KG Request to Amend Deed and Register Assignors: VIATRIS GMBH & CO. KG
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU72799/00A 1999-08-30 2000-08-26 Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof Ceased AU781505B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19941217 1999-08-30
DE19941217A DE19941217A1 (de) 1999-08-30 1999-08-30 Behandlung der Migräne durch Verabreichung von alpha-Liponsäure oder Derivaten derselben
PCT/EP2000/008315 WO2001015693A2 (de) 1999-08-30 2000-08-26 BEHANDLUNG DER MIGRÄNE DURCH VERABREICHUNG VON α-LIPONSÄURE ODER DERIVATEN DERSELBEN

Publications (2)

Publication Number Publication Date
AU7279900A AU7279900A (en) 2001-03-26
AU781505B2 true AU781505B2 (en) 2005-05-26

Family

ID=7920152

Family Applications (1)

Application Number Title Priority Date Filing Date
AU72799/00A Ceased AU781505B2 (en) 1999-08-30 2000-08-26 Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof

Country Status (32)

Country Link
US (1) US6251935B1 (sr)
EP (1) EP1207878B1 (sr)
JP (1) JP4773015B2 (sr)
KR (1) KR100624215B1 (sr)
CN (1) CN1170535C (sr)
AT (1) ATE232725T1 (sr)
AU (1) AU781505B2 (sr)
BG (1) BG65735B1 (sr)
BR (1) BR0013651A (sr)
CA (1) CA2382548C (sr)
CZ (1) CZ301789B6 (sr)
DE (2) DE19941217A1 (sr)
DK (1) DK1207878T3 (sr)
EE (1) EE04869B1 (sr)
ES (1) ES2190985T3 (sr)
HK (1) HK1046637A1 (sr)
HR (1) HRP20020168A2 (sr)
HU (1) HU229603B1 (sr)
IL (2) IL148068A0 (sr)
IS (1) IS2214B (sr)
MX (1) MXPA02002246A (sr)
NO (1) NO328692B1 (sr)
NZ (1) NZ517276A (sr)
PL (1) PL200928B1 (sr)
PT (1) PT1207878E (sr)
RS (1) RS50139B (sr)
RU (1) RU2232577C2 (sr)
SK (1) SK286260B6 (sr)
TR (1) TR200200461T2 (sr)
UA (1) UA71031C2 (sr)
WO (1) WO2001015693A2 (sr)
ZA (1) ZA200201637B (sr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2352144A1 (en) * 1998-11-25 2000-06-02 Yissum Research Development Company Of The Hebrew University In Jerusale M Scavenger compounds
US7030154B2 (en) 2002-06-07 2006-04-18 Juvenon, Inc. Stability of lipoic acid
US20050065094A1 (en) 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
US20090054513A1 (en) * 2007-08-22 2009-02-26 Response Scientific, Inc. Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
US7943163B2 (en) 2007-08-22 2011-05-17 Response Scientific, Inc. Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes
KR101493125B1 (ko) 2008-11-24 2015-02-12 세다르스-신나이 메디칼 센터 항산화성 캠토테신 유도체 및 이들의 항산화성 항종양성 나노구체
EP2429991B1 (en) 2009-05-15 2014-09-10 Redx Pharma Limited Redox drug derivatives
KR100935554B1 (ko) 2009-06-24 2010-01-07 주식회사 셀트리온제약 피페라진 다이티옥트산염 및 이를 포함하는 약제학적 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3380399A (en) * 1998-04-02 1999-10-25 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent
AU3970900A (en) * 1999-04-02 2000-10-23 Ipsen Pharma S.A.S. Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU620265A1 (ru) * 1977-02-21 1978-08-25 Центральный Ордена Трудового Красного Знамени Научно-Исследовательский Институт Курортологии И Физиотерапии Способ лечени атеросклероза сосудов головного мозга и гипертонической болезни
ES2043897T3 (es) * 1988-01-28 1994-01-01 Koeltringer Peter Preparado de combinacion, en especial para el tratamiento de enfermedades de las celulas nerviosas.
JPH03169813A (ja) * 1989-11-09 1991-07-23 Asta Pharma Ag 細胞保護作用を有する疼痛及び炎症性疾患及び／又はレトロウイルスに起因する病気の治療用医薬並びにその製法
US5569670A (en) * 1992-06-05 1996-10-29 Asta Medica Aktiengesellschaft Combination medications containing alpha-lipoic acid and related
DE4218572A1 (de) * 1992-06-05 1993-12-09 Asta Medica Ag Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
DE69331727D1 (de) * 1992-06-30 2002-04-25 Howard K Shapiro Verwendung einer kombination bestehend aus einem aminderivat oder aminverwandten derivat der benzoesäure und einem amino-polysaccharide zur herstellung eines medikaments fuer die behandlung von entzündlichen erkrankungen
DE4327426A1 (de) * 1993-08-14 1995-02-16 F H Erdaussiebung Gmbh Anbaugerät zum Sieben und Verfüllen von Erdmaterialien
DE4327462A1 (de) * 1993-08-16 1995-02-23 Carl Heinrich Dr Weischer Neue N-Acetyl-p-Aminophenol-Derivate zur Bekämpfung von Schmerzzuständen
DE4331168A1 (de) * 1993-09-14 1995-03-16 Carl Heinrich Dr Weischer Kombination von N-Acetyl-p-Aminophenol mit schwefelenthaltenden Carbonsäuren, wie z. B. alpha-Liponsäure und deren Derivate, zur Bekämpfung von Schmerzzuständen
EP0855396A1 (en) * 1997-01-22 1998-07-29 ASTA Medica Aktiengesellschaft Thioctic acid metabolites and methods of use thereof
IL123887A0 (en) * 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
AU8768098A (en) * 1997-08-04 1999-02-22 Christopher J. Berry Method of treating disease using a tocotrienol and alpha-lipoic acid r derivatives or an ester thereof
GB2333757B (en) * 1998-02-03 2001-06-27 Cheung Kwok Chung Sliding platform

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3380399A (en) * 1998-04-02 1999-10-25 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent
AU3970900A (en) * 1999-04-02 2000-10-23 Ipsen Pharma S.A.S. Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
BG65735B1 (bg) 2009-09-30
IL148068A (en) 2007-06-03
NO328692B1 (no) 2010-04-26
TR200200461T2 (tr) 2002-08-21
EP1207878A2 (de) 2002-05-29
RU2232577C2 (ru) 2004-07-20
IS6284A (is) 2002-02-26
NO20020917D0 (no) 2002-02-25
EE04869B1 (et) 2007-08-15
PL352741A1 (en) 2003-09-08
YU15002A (sh) 2005-03-15
IS2214B (is) 2007-03-15
CA2382548C (en) 2007-07-03
ATE232725T1 (de) 2003-03-15
WO2001015693A2 (de) 2001-03-08
BG106407A (en) 2002-10-31
CN1170535C (zh) 2004-10-13
NO20020917L (no) 2002-02-25
CA2382548A1 (en) 2001-03-08
SK286260B6 (sk) 2008-06-06
HK1046637A1 (en) 2003-01-24
PL200928B1 (pl) 2009-02-27
SK2902002A3 (en) 2002-09-10
BR0013651A (pt) 2002-05-07
PT1207878E (pt) 2003-07-31
CN1371280A (zh) 2002-09-25
DK1207878T3 (da) 2003-06-16
EE200200098A (et) 2003-04-15
ES2190985T3 (es) 2003-09-01
RS50139B (sr) 2009-03-25
IL148068A0 (en) 2002-09-12
UA71031C2 (uk) 2004-11-15
CZ2002655A3 (cs) 2002-07-17
HUP0203025A3 (en) 2004-12-28
WO2001015693A3 (de) 2001-12-20
DE19941217A1 (de) 2001-03-15
US6251935B1 (en) 2001-06-26
ZA200201637B (en) 2003-01-29
CZ301789B6 (cs) 2010-06-23
KR20020060168A (ko) 2002-07-16
JP2003508438A (ja) 2003-03-04
DE50001301D1 (de) 2003-03-27
HU229603B1 (en) 2014-02-28
NZ517276A (en) 2004-06-25
AU7279900A (en) 2001-03-26
KR100624215B1 (ko) 2006-09-18
MXPA02002246A (es) 2003-08-20
HUP0203025A2 (hu) 2002-12-28
HRP20020168A2 (en) 2003-06-30
EP1207878B1 (de) 2003-02-19
JP4773015B2 (ja) 2011-09-14

Similar Documents

Publication Publication Date Title
AU2002340971B2 (en) Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders
Vyth et al. Survival in patients with amyotrophic lateral sclerosis, treated with an array of antioxidants
AU781505B2 (en) Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof
JP2022507533A (ja) 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
AU2005270573B2 (en) Novel formulation for L-tryptophane comprising carbidopa/benserazide
CA2840363A1 (en) Compositions comprising a central nervous system stimulant and select micronutrients useful in the treatment of chronic fatigue
BR112020005856A2 (pt) uso de uma composição contendo benzoato para tratar encefalopatia da glicina
CA3216699A1 (en) Blood carnitine-increasing agent
EA006896B1 (ru) Применение дезоксипеганина для лечения клинической депрессии
WO2000038678A1 (fr) Composition en tant que medicament et utilisation d'une telle composition pour l'obtention d'un medicament destine a l'anesthesie, notamment medicament analgesique
JP6926192B2 (ja) Ｎ，ｎ−ビス−２−メルカプトエチルイソフタルアミドの新規用途
RU2345775C1 (ru) Нестероидное противовоспалительное лекарственное средство
MXPA01012644A (es) Combinaciones antilipemicas que comprenden inhibidores de hmg-coa reductasa y carnitina.
WO2023156275A1 (en) Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor
JPH0449235A (ja) 痴呆治療剤